Literature DB >> 28836053

New classification for the thoracic paraaortic lymph nodes of patients with esophageal squamous cell carcinoma.

Masaaki Yamamoto1, Makoto Yamasaki2, Koji Tanaka1, Yasuhiro Miyazaki1, Tomoki Makino1, Tsuyoshi Takahashi1, Yukinori Kurokawa1, Kiyokazu Nakajima1, Shuji Takiguchi1, Masaki Mori1, Yuichiro Doki1.   

Abstract

PURPOSE: To create a new classification for the thoracic paraaortic lymph nodes (No. 112ao) of patients with esophageal squamous cell carcinoma (ESCC). Classification of these nodes in ESCC patients has been the focus of very few reports.
METHODS: The subjects of this study were 27 patients with positive No. 112ao nodes on computed tomography (CT) images before treatment. We divided the No. 112ao nodes into No. 112aoA, located on the esophageal side as anterior No. 112ao nodes, and No. 112aoP, located on the opposite side of the esophagus as posterior No. 112ao nodes. We examined the association between No. 112aoA and No. 112aoP and clinicopathological factors. Recurrence-free survival (RFS) was compared between the No. 112aoA- and No. 112aoP-positive groups.
RESULTS: There were 12 patients in the No. 112aoA-positive group and 15 patients in the No. 112aoP-positive group. The No. 112aoP-positive group had significantly worse RFS than the No. 112aoA-positive group (p = 0.004). Cox multivariate analysis of RFS revealed that No. 112aoP positivity was an independent prognostic factor (p = 0.043).
CONCLUSIONS: Our new classification of No. 112ao nodes into No. 112aoA and No. 112aoP is useful clinically. No. 112aoP could correspond to the clinical N4 category of patients with ESCC.

Entities:  

Keywords:  Classification; Esophageal cancer; Paraaortic lymph nodes

Mesh:

Year:  2017        PMID: 28836053     DOI: 10.1007/s00595-017-1576-9

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  16 in total

1.  Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients.

Authors:  Keisuke Kosumi; Yoshifumi Baba; Takatsugu Ishimoto; Kazuto Harada; Kenichi Nakamura; Mayuko Ohuchi; Yuki Kiyozumi; Daisuke Izumi; Ryuma Tokunaga; Katsunobu Taki; Takaaki Higashi; Tatsunori Miyata; Junji Kurashige; Yukiharu Hiyoshi; Shiro Iwagami; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2015-06-03       Impact factor: 2.549

2.  Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  J Surg Oncol       Date:  2012-02-27       Impact factor: 3.454

3.  Novel technique for dissection of subcarinal and main bronchial lymph nodes using a laparoscopic transhiatal approach for esophageal cancer.

Authors:  Atsushi Shiozaki; Hitoshi Fujiwara; Hirotaka Konishi; Ryo Morimura; Yasutoshi Murayama; Shuhei Komatsu; Yoshiaki Kuriu; Hisashi Ikoma; Takeshi Kubota; Masayoshi Nakanishi; Daisuke Ichikawa; Kazuma Okamoto; Chouhei Sakakura; Eigo Otsuji
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

4.  Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Ann Surg       Date:  2015-08       Impact factor: 12.969

Review 5.  History of lymphadenectomy for esophageal cancer and the future prospects for esophageal cancer surgery.

Authors:  Hiromasa Fujita
Journal:  Surg Today       Date:  2014-02-13       Impact factor: 2.549

6.  Impact of number of [(18)F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer.

Authors:  H Miyata; M Yamasaki; T Makino; M Tatsumi; Y Miyazaki; T Takahashi; Y Kurokawa; S Takiguchi; M Mori; Y Doki
Journal:  Br J Surg       Date:  2015-10-27       Impact factor: 6.939

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Japanese Classification of Esophageal Cancer, 11th Edition: part II and III.

Authors: 
Journal:  Esophagus       Date:  2016-11-10       Impact factor: 4.230

9.  Japanese Classification of Esophageal Cancer, 11th Edition: part I.

Authors: 
Journal:  Esophagus       Date:  2016-11-10       Impact factor: 4.230

10.  Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).

Authors:  M Yamasaki; T Yasuda; M Yano; M Hirao; K Kobayashi; K Fujitani; S Tamura; Y Kimura; H Miyata; M Motoori; O Shiraishi; T Makino; T Satoh; M Mori; Y Doki
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.